TIMOTHY COVER, MD
Osteopathic Medicine in Nashville, TN
License number
Tennessee MD20843
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
3601 Tvc, Nashville, TN 37232
Phone
(615) 322-3000
Personal information
See more information about TIMOTHY COVER at radaris.comName
Address
Phone
2804 W Linden Ave, Nashville, TN 37212
Nashville, TN
2804 Linden Ave, Nashville, TN 37212
201 Vamc, Nashville, TN 37201
Organization information
See more information about TIMOTHY COVER at bizstanding.comTimothy Cover MD
1161 21 Ave S, Nashville, TN 37232
Industry:
Internist
Phone:
(615) 322-2035 (Phone)
Description:
There are 22 doctors at this site. Surgery is not performed at this site.
Timothy Lee Cover
Timothy Cover MD
201 Va Medical Ctr, Nashville, TN 37203
Categories:
Infectious Disease Physicians & Surgeons, Physicians & Surgeons
Phone:
(615) 327-4751 (Phone)
Products:
Military & Veteran's Services
Additional:
Federal
Professional information
Timothy Cover, Nashville TN
Specialties:
Internal Medicine, Infectious Disease, Pediatric Infectious Diseases
Work:
Vanderbilt Medical Group Specialist
3601 The Vanderbilt Clinic, Nashville, TN 37232
3601 The Vanderbilt Clinic, Nashville, TN 37232
Education:
Duke University(1984)
Dr. Timothy Cover, Nashville TN - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
A2200 Medical Center Dr N, Nashville 37232
Nashville Office
1211 Medical Center Dr, Nashville 37232
(615) 322-5000 (Phone), (615) 343-7317 (Fax)
VANDERBILT UNIVERSITY
1161 21St Ave S SUITE A3310, Nashville 37232
(615) 322-2035 (Phone), (615) 343-6160 (Fax)
3601 Tvc, Nashville 37232
(615) 322-3000 (Phone)
Nashville Office
1211 Medical Center Dr, Nashville 37232
(615) 322-5000 (Phone), (615) 343-7317 (Fax)
VANDERBILT UNIVERSITY
1161 21St Ave S SUITE A3310, Nashville 37232
(615) 322-2035 (Phone), (615) 343-6160 (Fax)
3601 Tvc, Nashville 37232
(615) 322-3000 (Phone)
Certifications:
Infectious Disease, 1990, Internal Medicine, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
A2200 Medical Center Dr N, Nashville 37232
3601 Tvc, Nashville 37232
VANDERBILT UNIVERSITY
1161 21St Ave S SUITE A3310, Nashville 37232
Nashville Office
1211 Medical Center Dr, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
3601 Tvc, Nashville 37232
VANDERBILT UNIVERSITY
1161 21St Ave S SUITE A3310, Nashville 37232
Nashville Office
1211 Medical Center Dr, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
Education:
Medical School
Duke University
Graduated: 1984
Ms Hershey Med Ctr-Penn St
University Of Colorado
Vanderbilt University
Duke University
Graduated: 1984
Ms Hershey Med Ctr-Penn St
University Of Colorado
Vanderbilt University
Taga Gene And Methods For Detecting Predisposition To Peptic Ulceration And Gastric Carcinoma
US Patent:
5733740, Mar 31, 1998
Filed:
Sep 30, 1994
Appl. No.:
8/316397
Inventors:
Timothy L. Cover - Nashville TN
Martin J. Blaser - Nashville TN
Harry Kleanthous - Cambridge MA
Murali K. R. Tummuru - Nashville TN
Martin J. Blaser - Nashville TN
Harry Kleanthous - Cambridge MA
Murali K. R. Tummuru - Nashville TN
Assignee:
Vanderbilt University - Nashville TN
OraVax, Inc. - Cambridge MA
OraVax, Inc. - Cambridge MA
International Classification:
G01N 33554, G01N 33569
US Classification:
435 732
Abstract:
An isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, or an antigenic fragment thereof, wherein the antigen is associated with peptic ulceration. The present invention also provides methods of detecting the presence of a Helicobacter pylori strain possessing the 120-128 kilodalton antigen in a subject, comprising the steps of contacting an antibody-containing sample from the subject with a detectable amount of the tagA antigen or antigenic polypeptide of the present invention and detecting the binding of the antigen or fragment and the antibody. The detection of a strain expressing the TagA antigen is an indication of predisposition to peptic ulceration and gastric carcinoma. A mutant H. pylori not expressing a functional TagA antigen is also provided.
Taga Gene And Methods For Detecting Predisposition To Peptic Ulceration And Gastric Carcinoma
US Patent:
6153390, Nov 28, 2000
Filed:
Mar 1, 1999
Appl. No.:
9/259437
Inventors:
Timothy L. Cover - Nashville TN
Martin J. Blaser - Nashville TN
Harry Kleanthous - Cambridge MA
Murali K. R. Tummuru - Nashville TN
Martin J. Blaser - Nashville TN
Harry Kleanthous - Cambridge MA
Murali K. R. Tummuru - Nashville TN
Assignee:
Vanderbilt University - Nashville TN
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
The present invention provides an isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, or an antigenic fragment thereof, wherein the antigen is associated with peptic ulceration. The present invention also provides methods of detecting the presence of a Helicobacter pylori strain possessing the 120-128 kilodalton antigen in a subject, comprising the steps of contacting an antibody-containing sample from the subject with a detectable amount of the tagA antigen or antigenic polypeptide of the present invention and detecting the binding of the antigen or fragment and the antibody. The detection of a strain expressing the TagA antigen is an indication of predisposition to peptic ulceration and gastric carcinoma. A mutant H. pylori not expressing a functional TagA antigen is also provided.
Vacuolating Toxin-Deficient H. Pylori
US Patent:
5721349, Feb 24, 1998
Filed:
Feb 23, 1994
Appl. No.:
8/200232
Inventors:
Timothy L. Cover - Nashville TN
Martin J. Blaser - Nashville TN
Martin J. Blaser - Nashville TN
Assignee:
Vanderbilt University - Nashville TN
International Classification:
A61K 39106, C12N 1531, C12N 120, C07H 2104
US Classification:
536 221
Abstract:
An isolated nucleic acid encoding the Helicobacter pylori vacuolating toxin, consisting of the nucleotides 101 through 3964 of the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. An isolated nucleic acid from Helicobacter pylori comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:3 is provided. Isolated nucleic acids that selectively hybridize with the nucleic acids of the invention are provided. Also provided is a genetically altered mutant strain of H. pylori that does not express a functional vacuolating toxin. Purified proteins encoded by the nucleic acids of the invention are provided. A composition comprising an immunogenic amount of a protein or mutant strain of the invention in a pharmaceutically acceptable carrier is provided. A method of immunizing a subject against infection by H. pylori, comprising administering to the subject an immunogenic composition of the invention is provided.
Purified Vacuolating Toxin From Helicobacter Pylori And Methods To Use Same
US Patent:
6054132, Apr 25, 2000
Filed:
Aug 2, 1994
Appl. No.:
8/284747
Inventors:
Timothy L. Cover - Nashville TN
Martin J. Blaser - Nashville TN
Martin J. Blaser - Nashville TN
Assignee:
Vanderbilt University - Nashville TN
International Classification:
A61K 3902
US Classification:
4242361
Abstract:
This invention relates to a purified Helicobacter pylori vacuolating toxin and methods to use this toxin to produce protective antibodies against H. pylori infection. Antiserum to this antigen can be used to detect the toxin. Methods to detect anti-toxin antibodies determine the susceptibility of a patient to develop peptic ulcer disease, gastric carcinoma, or other clinical consequences of H. pylori infection.
Purified Vacuolating Toxin From Helicobacter Pylori And Methods To Use Same
US Patent:
6013463, Jan 11, 2000
Filed:
Jun 7, 1995
Appl. No.:
8/473265
Inventors:
Timothy L. Cover - Nashville TN
Martin J. Blaser - Nashville TN
Martin J. Blaser - Nashville TN
Assignee:
Vanderbilt University - Nashville TN
International Classification:
G01N 3353
US Classification:
435 792
Abstract:
This invention relates to a purified Helicobacter pylori vacuolating toxin and methods to use this toxin to produce protective antibodies against H. pylori infection. Antiserum to this antigen can be used to detect the toxin. Methods to detect anti-toxin antibodies determine the susceptibility of a patient to develop peptic ulcer disease, gastric carcinoma, or other clinical consequences of H. pylori infection.
Purified Vacuolating Toxin From Helicobacter Pylori And Methods To Use Same
US Patent:
5859219, Jan 12, 1999
Filed:
Oct 27, 1994
Appl. No.:
8/295643
Inventors:
Timothy L. Cover - Nashville TN
Martin J. Blaser - Nashville TN
Martin J. Blaser - Nashville TN
Assignee:
Vanderbilt University - Nashville TN
International Classification:
A61K 39106, C12N 1531, C12N 120, C07H 2104
US Classification:
536 221
Abstract:
This invention relates to a purified Helicobacter pylori vacuolating toxin and methods to use this toxin to produce protective antibodies against H. pylori infection. Antiserum to this antigen can be used to detect the toxin. Methods to detect anti-toxin antibodies determine the susceptibility of a patient to develop peptic ulcer disease, gastric carcinoma, or other clinical consequences of H. pylori infection.
Helicobacter Taga Gene Fusion Protein
US Patent:
5876943, Mar 2, 1999
Filed:
Mar 2, 1998
Appl. No.:
/034306
Inventors:
Timothy L. Cover - Nashville TN
Martin J. Blaser - Nashville TN
Harry Kleanthous - Cambridge MA
Murali K. R. Tummuru - Nashville TN
Martin J. Blaser - Nashville TN
Harry Kleanthous - Cambridge MA
Murali K. R. Tummuru - Nashville TN
Assignee:
Vanderbilt University - Nashville TN
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
The present invention provides an isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, or an antigenic fragment thereof, wherein the antigen is associated with peptic ulceration. The present invention also provides methods of detecting the presence of a Helicobacter pylori strain possessing the 120-128 kilodalton antigen in a subject, comprising the steps of contacting an antibody-containing sample from the subject with a detectable amount of the tagA antigen or antigenic polypeptide of the present invention and detecting the binding of the antigen or fragment and the antibody. The detection of a strain expressing the TagA antigen is an indication of predisposition to peptic ulceration and gastric carcinoma. A mutant H. pylori not expressing a functional TagA antigen is also provided.
Taga Gene And Methods For Detecting Predisposition To Peptic Ulceration
US Patent:
5403924, Apr 4, 1995
Filed:
Apr 26, 1993
Appl. No.:
8/053614
Inventors:
Timothy L. Cover - Nashville TN
Murali K. R. Tummuru - Nashville TN
Martin J. Blaser - Nashville TN
Murali K. R. Tummuru - Nashville TN
Martin J. Blaser - Nashville TN
Assignee:
Vanderbilt University - Nashville TN
International Classification:
C07H 2102, C07H 2104
US Classification:
536 231
Abstract:
The present invention provides an isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, or an antigenic fragment thereof, wherein the antigen is associated with peptic ulceration. The present invention also provides methods of detecting the presence of a Helicobacter pylori strain possessing the 120-128 kilodalton antigen in a subject, comprising the steps of contacting an antibody-containing sample from the subject with a detectable amount of the tagA antigen or antigenic fragment of the present invention and detecting the reaction of the antigen or fragment and the antibody. A mutant H. pylori not expressing a functional tagA antigen is also provided.